|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||397.50 - 402.50|
|52 Week Range||212.50 - 420.50|
|PE Ratio (TTM)||81.89|
|Earnings Date||Aug 15, 2017 - Aug 21, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||419.13|
COPENHAGEN, Denmark, August 9, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces the subscription price and the number of new shares to be issued to Johnson & Johnson Innovation - JJDC, Inc. ...
Danish biotech company Bavarian Nordic has expanded its collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson, to also grant the U.S. drugmaker the exclusive rights to its MVA-BN technology for vaccine programmes targeting hepatitis B and HIV-1.
COPENHAGEN, Denmark, July 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces additional details regarding the issue of shares to Johnson & Johnson Innovation - JJDC, Inc. ("J&J") ...